Research progress of PD-1 and PD-L1 in the immune of sepsis
10.3760/cma.j.cn121382-20230308-00314
- VernacularTitle:PD-1和PD-L1在脓毒症免疫反应中的研究进展
- Author:
Yifan LI
1
;
Danying ZHANG
;
Mengqing WANG
;
Zhaofen LIN
Author Information
1. 上海长征医院急诊与危重症医学科，上海 200003
- Keywords:
Sepsis;
Programmed death receptor-1;
Programmed death-ligand 1;
Immunosuppression
- From:
International Journal of Biomedical Engineering
2023;46(3):270-274
- CountryChina
- Language:Chinese
-
Abstract:
Sepsis is currently the leading cause of death in the intensive care unit, and its survivors also experience long-term immunosuppression and high rates of recurrent infections. At present, the clinical treatment of sepsis is still based on antibiotics, intravenous rehydration, and vasopressors, and there is no targeted drug treatment. However, as the rate of antibiotic resistance continues to increase, immunotherapy is highly anticipated as a new treatment. Patients with sepsis are often accompanied by acute leukocyte immune dysfunction and immunosuppression, which may be an important risk factor for the increasing morbidity and mortality of patients. Targeted inhibition of specific cell surface inhibitory immune checkpoint receptors and ligands, such as programmed death receptor-1 (PD-1), programmed death-ligand 1 (PD-L1), and other targets, can improve the host’s resistance to infection. In this paper, the research progress of PD-1 and PD-L1 in the immune response to sepsis was summarized to provide a theoretical basis for their further application in the treatment of sepsis in the future.
